Tyra Biosciences, Inc. (TYRA) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Tyra Biosciences, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biotechnology company developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform for rapid drug design.
Key Assets: Lead oral small molecule dabogratinib (FGFR3-selective) for urothelial cancers and skeletal dysplasia; TYRA-430 (FGFR4/3 biased) for hepatocellular carcinoma; and TYRA-200 (FGFR1/2/3 inhibitor) for cholangiocarcinoma.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(119.9) million | $(86.5) million |
| Operating Expenses | $132.8 million | $104.2 million |
| Research & Development (R&D) | $102.9 million | $80.1 million |
| General & Administrative (G&A) | $29.8 million | $24.1 million |
| Cash, Cash Equivalents & Marketable Securities | $256.0 million | $341.4 million |
| Accumulated Deficit | $(371.3) million | $(251.3) million |
| Net Cash Used in Operating Activities | $(95.1) million | $(69.8) million |
Note: The company has no debt and no revenue. Liquidity is supported by cash reserves and marketable securities.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $33.5 million (38.7%) year-over-year, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose $22.9 million, attributed to an $11.5 million increase in external costs for dabogratinib clinical trials (SURF302, BEACH301, and startup for SURF303) and a $3.4 million increase for TYRA-430 development.
- Interest Income Decline: Other income decreased by $4.9 million to $12.8 million due to lower interest rates and reduced cash balances.
- Stock-Based Compensation: Increased by $5.2 million to $28.0 million, reflecting headcount growth and new grants.
Guidance, Outlook, and Risks
Clinical Outlook & Milestones:
- Dabogratinib (3x3 Strategy):
- SURF303 (LG-UTUC): First patient dosing anticipated in 2026.
- SURF302 (IR NMIBC): Initial 3-month Complete Response (CR) data expected by end of H1 2026.
- BEACH301 (Achondroplasia): Initial safety sentinel cohort data (6-month height velocity) expected in H2 2026.
- TYRA-430 & TYRA-200: Phase 1 trials ongoing; seeking proof-of-concept in HCC and ICC, respectively.
Liquidity Outlook: Management believes existing cash and marketable securities ($256.0 million as of Dec 31, 2025) are sufficient to fund operations through at least 2027.
Key Risks:
- Capital Requirements: Significant additional capital will be required to advance clinical trials and commercialize products. Failure to secure funding could force delays or program termination.
- Clinical Uncertainty: Early-stage clinical data is not predictive of future results; trials may fail to demonstrate efficacy or safety.
- Regulatory & Manufacturing: Reliance on third-party manufacturers and CROs; potential for regulatory delays or rejection of companion diagnostics.
- Competition: Intense competition in FGFR-targeted therapies (e.g., erdafitinib, pemigatinib) and skeletal dysplasia treatments (e.g., vosoritide).
Investor Verification Checklist
- Cash Runway: Verify the $256 million cash balance and the specific assumptions used to project funding through 2027.
- Clinical Trial Enrollment: Monitor patient enrollment rates for SURF302 and BEACH301 to ensure H1/H2 2026 data readout timelines are met.
- ATM Facility: Review the $150 million "at-the-market" sales agreement with TD Securities (May 2025) for any utilization or termination notices.
- Stock-Based Compensation: Assess the $75.8 million of unrecognized stock-based compensation cost and its impact on future operating expenses.
- Patent Expiry: Confirm the timeline for patent expirations (2040-2046) relative to expected commercialization dates.